Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + tislelizumab
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Apatinib + tislelizumab is an investigational combination therapy consisting of two agents: - Apatinib, a small molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking angiogenesis and tumor blood supply. - Tislelizumab, a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. This combination is being studied for the treatment of various advanced cancers, including renal cell carcinoma and gastric cancer. The rationale for combining these agents is to leverage both antiangiogenic effects (apatinib) and immunomodulatory activity (tislelizumab) to improve clinical outcomes in patients with advanced malignancies[1][2][3][4][5][6].
- Other names
- apatinib plus tislelizumabtislelizumab combined with apatinib
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on apatinib + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + tislelizumab.